One mRNA codebase, but delivery, safety and regulatory gates per disease Sequence as code mRNA codebase V940: code per tumor swap to re-target V940 melanoma candidate app Lung cancer candidate app Pancreatic candidate app Delivery gate LNP into cells Safety / immunogenicity gate Regulatory gate per-program FDA De-risking source value = disclosed trial data + regulatory decisions, not platform shorthand Musk 2026 restates the 2020 framing - concedes "obvious misuse during Covid" one gate app-store deploy any disease = new app optionality implied, gates collapsed analogy: one codebase feeds many apps - treated as a single deploy reality: each program clears delivery, safety and regulatory before revenue ok ok ok past the gates on Phase 3 filing + magnitude pending V940 post-Phase 3: gates cleared - filing and magnitude still pending